New Ask Claude or ChatGPT about any stock, using Bullpen. Bullpen in Claude or ChatGPT. 7 days free

Wednesday, November 18, 2026

Back to the front page

From X

Calvin Blissett on X

$PAHC: 9x cash flow. 26% ROE Animals have to be healthy whether the economy is good or bad, and livestock producers have an economic incentive to spend money on products that reduce mortality, improve feed conversion, increase yield or prevent disease. 22% Adj EBITDA margin. JPM $55 PT. The company operates through the following business divisions: Animal Health division manufactures and sells animal health products such as antibacterial, anticoccidials, nutritional specialty products and vaccines used in the animal health industry to treat or to prevent bacterial diseases to improve the animal’s health. Mineral Nutrition division manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds. Performance Products division manufactures and markets various specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries. The most tangible new initiative is the planned closure of Chicago Heights, Illinois. Phibro acquired the facility as part of the Zoetis deal, reviewed its manufacturing network and decided it no longer made economic sense to keep the facility open. Production is expected to cease in summer 2027, affecting roughly 100 employees. Production will be shifted to other Phibro facilities and selected third-party manufacturers. Phibro Animal Health Corporation Management says the point is straightforward: align manufacturing capacity with future needs, improve efficiency and strengthen competitiveness. Phibro Animal Health Corporation The company expects approximately $10m of one-time cash costs and about $10m of capex, with eventual annual EBITDA benefit estimated around $15–20m, largely from FY2028 onward Regulatory optionality: Brazil virginiamycin One of the most interesting hidden catalysts is virginiamycin in Brazil. FY2027 guidance assumes only minimal sales because Phibro has not yet obtained the required therapeutic indications. FY2026 virginiamycin sales in Brazil were roughly $27m. Management explicitly said a favorable regulatory result could therefore provide modest upside to guidance.

Research Roundup Vol. LXI

Nvidia faced China workaround enforcement concerns as technology fell 6%; energy rose 4.5%, while the company raised eFY28 revenue growth…

NVIDIA Corp Earnings Update: Q3 2026

NVIDIA’s fiscal third-quarter 2027 results are its first earnings report since Jensen Huang’s resignation as CEO.

PATK · long

Patrick Industries

Patrick Industries (PATK) is pitched long on its current valuation.

S&P Global

S&P Global’s valuation swung from 7x earnings in 2009 to 50x in 2024 as ratings, indices and proprietary data expanded through acquisitions…

Publications we follow

Every publication on this site, hand-picked.

130 publications

Newsletters 110

Seeking Alpha 98 of 301

X accounts we follow

Every account on this site, hand-picked.

94 accounts

Investor letters we follow

383 firms

Sectors

Ordered by how often our editor reaches for them.